UNCOVERED: 14 | History Defined

Stock Of The Day: Another Breakout For Eli Lilly?

Trading is quiet in Eli Lilly and Co (NYSE:LLY) on Thursday. The stock has stalled out at a resistance level.

Benzinga · Aug 28, 2025

Warning over Mounjaro ‘golden dose’ as users panic over shortages and soaring prices

With the price of Mounjaro to rise in September, some users are using leftover medication in syringes to create an extra dose

The Independent UK · Aug 28, 2025

UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears

Patients across the United Kingdom are struggling to obtain the weight-loss and diabetes drug Mounjaro as demand surges ahead of a sharp price increase set for September.

Benzinga · Aug 28, 2025

Sales of Mounjaro weight loss jab to UK suspended as pharmacies hit by shortage ahead of price hike

Boots and Lloyds pharmacies among those running low after users stockpile drug ahead of price hike

The Independent UK · Aug 27, 2025

New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients.

Benzinga · Aug 27, 2025

‘I lost more than 2 stone on Mounjaro - but my hair started to fall out’

Rhiannon Anne Griffiths-Bowen says the weight-loss benefits of taking Mounjaro outweighed the issue of hair loss

The Independent UK · Aug 27, 2025

Eli Lilly Stock Jumps On Weight-Loss Pill Trial

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio. 

Benzinga · Aug 26, 2025

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

MarketBeat · Aug 26, 2025

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK · Aug 26, 2025

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Benzinga · Aug 26, 2025